Applicant, as named in the Orange Book
Deciphera Pharms
Next listed expiry: Qinlock on 6 Oct 2042. 2 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Qinlock NDA 213973 ripretinib | 6 Oct 2042 patent, carve-out possible |
| Romvimza NDA 219304 ยท 3 strengths vimseltinib | 30 Apr 2045 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.